Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 15/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31050105 | 0.84 | ALDH1A1 (0.61) | CYP2C9CYP2C19ALDH1A1MAPK1TDP1 | |
| SCHEMBL337203 | 0.84 | ALDH1A1 (0.61) | CYP2C9CYP2C19ALDH1A1MAPK1TDP1 | |
| SCHEMBL25049604 | 0.83 | CA12 (0.54) | CYP2C9CYP2C19TDP1CA12CA1 | |
| SCHEMBL15351663 | 0.83 | CYP2C9 (0.51) | CYP2C9CYP2C19ALDH1A1MAPK1TDP1 | |
| SCHEMBL31629408 | 0.82 | MAPK1 (0.46) | ALDH1A1MAPK1TDP1L3MBTL1P2RY12 | |
| SCHEMBL3950224 | 0.81 | CYP2C9 (0.50) | CYP2C9CYP2C19ALDH1A1MAPK1TDP1 | |
| SCHEMBL25049197 | 0.81 | CYP2C9 (0.50) | CYP2C9CYP2C19ALDH1A1MAPK1CA12 | |
| SCHEMBL5320922 | 0.81 | CYP2C9 (0.50) | CYP2C9CYP2C19ALDH1A1MAPK1TDP1 | |
| SCHEMBL14830838 | 0.81 | CYP2C9 (0.47) | CYP2C9CYP2C19ALDH1A1MAPK1TDP1 | |
| SCHEMBL14831259 | 0.80 | ALDH1A1 (0.51) | CYP2C9CYP2C19ALDH1A1MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300476-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| EP-2300476-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| CN-102105473-A | Tricyclic nitrogen containing compounds and their use as antibacterials | GLAXO GROUP LTD | 2011-06-22 | — | — | CN | disclosed |
| EP-2300476-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| WO-2009141398-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141398-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306089-A1 | COMPOUNDS | SDHA, NQO1, SDHB | CYP2C9 59/4885CYP2C19 47/4885ALDH1A1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.